BPC-157 + TB-500 (Thymosin Beta-4 Fragment) is a research blend combining two of the most extensively studied peptides in the regenerative biology literature. BPC-157 is a synthetic 15-amino-acid (pentadecapeptide) sequence derived from a body-protective compound first isolated from human gastric juice. TB-500 is the active fragment of thymosin beta-4, corresponding to the actin-sequestering region of the full 43-amino-acid protein. The pairing is designed to address tissue repair through two distinct, non-overlapping cellular mechanisms: vascular angiogenesis and mucosal integrity (BPC-157) alongside cytoskeletal remodeling and cell migration (TB-500).
BPC-157 acts through multiple parallel signaling pathways. Its most characterized angiogenic mechanism involves upregulation of VEGFR-2 (Vascular Endothelial Growth Factor Receptor 2) expression, which Hsieh and colleagues demonstrated in a 2017 mechanistic study (PMID 27847966) to be central to BPC-157 pro-angiogenic effects in both cell culture and rodent models. Beyond angiogenesis, BPC-157 influences the nitric oxide (NO) system — both directly through eNOS upregulation and indirectly through interaction with the NO-synthase pathway — which contributes to vascular tone regulation and mucosal protection. A 2026 study (PMID 39935793) identified acetylcholinesterase inhibition as a novel mechanism, implicating BPC-157 in cholinergic signaling relevant to gastrointestinal motility and enteric nervous system function. BPC-157 also demonstrates gastric cytoprotection independently of prostaglandins.
TB-500 acts by binding and sequestering G-actin monomers, the globular form of actin that polymerizes into filamentous F-actin networks. By modulating the G-actin/F-actin equilibrium, TB-500 regulates cytoskeletal dynamics in ways that promote cell migration into injury zones. Kleinman and colleagues (PMID 27450738) documented TB-500 role in dermal healing, identifying cell migration as the primary mechanism. Because actin dynamics are fundamental to nearly all motile cell types (fibroblasts, endothelial cells, keratinocytes, satellite cells), TB-500 has been studied across musculoskeletal, cardiac, dermal, and neurological repair contexts.
The mechanistic logic for combining these peptides is that tissue repair requires both adequate blood supply (angiogenesis, addressed by BPC-157 VEGFR-2 activation) and efficient cellular recruitment to the injury site (cytoskeletal remodeling and migration, addressed by TB-500 actin sequestration). Neither mechanism substitutes for the other. In a tendon or ligament injury model, BPC-157 can promote neovascularization to restore nutrient delivery, while TB-500 facilitates fibroblast migration into the repair zone — the two processes proceeding simultaneously rather than sequentially.
- Musculoskeletal and connective tissue repair models — tendon-to-bone healing, ligament regeneration, rotator cuff repair models, and Achilles tendon healing timelines in rodent injury preparations
- Wound closure and dermal healing — scratch assay cell migration studies, wound-closure rate measurement, scar formation kinetics, and comparison of single-peptide vs. stacked protocols
- Angiogenesis and vascular biology — tube formation assays (HUVEC), Matrigel plug models, microvessel density measurements in ischemic tissue, and VEGFR-2 phosphorylation studies
- Gastrointestinal mucosal protection — NSAID-induced ulcer models, ethanol-mucosal lesion studies, IBD cell culture models, and gastric cytoprotection research independent of prostaglandins
- Post-injury soft tissue remodeling — muscle satellite cell activation, cardiac repair following ischemia-reperfusion injury, and post-surgical tissue remodeling timelines
- Comparative blend-vs.-single-peptide research — dose-matched controls allowing researchers to decompose which outcomes arise from each component vs. from additive or synergistic interaction
- Cholinergic and enteric nervous system research — BPC-157 acetylcholinesterase inhibition (2026) opens neurobiological research applications in enteric function and autonomic regulation
The BPC-157 + TB-500 combination is among the most commercially active research peptide blends on the market. Peptides.SO currently tracks 77 active supplier listings for this blend, giving researchers the broadest cross-supplier comparison available for any stacked peptide product on the platform. Pricing spans from approximately $0.10/mg (large-format bulk lots) to $700 per vial, with a platform average of approximately $108 per listing. The price spread reflects variation in vial size (commonly 2mg BPC-157 + 2mg TB-500 up to 10mg + 10mg blended formats), peptide ratio (1:1 or 2:1 BPC-157:TB-500 by weight), lyophilization quality, HPLC purity tier, and third-party testing documentation.
When comparing listings, verify the stated ratio of BPC-157 to TB-500 per vial — the per-milligram price means different things depending on vial composition. Suppliers with publicly available third-party COAs showing individual compound purity above 98% HPLC command a justified premium.
They act through non-overlapping cellular mechanisms: BPC-157 primarily drives angiogenesis and mucosal protection via VEGFR-2 and NO pathways, while TB-500 promotes cell migration through actin cytoskeleton remodeling. Together, they address both the vascular supply and the cellular recruitment aspects of tissue repair.
Published literature on interaction effects between BPC-157 and TB-500 in combination is limited. Researchers using the blend should design controls (BPC-157 alone, TB-500 alone, both combined) to isolate which outcomes are attributable to each component vs. co-administration.
Published rodent studies typically use molar-equivalent or weight-equivalent dosing of each compound separately. Commercial blends commonly offer 1:1 or 2:1 (BPC-157:TB-500) by weight. The appropriate ratio depends on the biological endpoint being studied.
A legitimate COA should show HPLC purity chromatograms for each compound separately, mass spectrometry confirmation of both molecular weights, and endotoxin levels below 1 EU/mg. The testing lab should be identifiable and contactable.
See also: BPC-157 (single compound) · GHK-Cu + BPC-157 + TB-500 · BPC-157 + TB-500 + KPV + GHK-Cu · BPC-157 Complete Research Guide · BPC-157 vs TB-500 Comparison
- Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." J Mol Med (Berl). 2017. PMID: 27847966
- Sikiric P, et al. "Stable Gastric Pentadecapeptide BPC 157 as Useful Cytoprotective Peptide Therapy." Curr Pharm Des. 2018. PMID: 30112998
- Kleinman HK, et al. "Thymosin beta4 Promotes Dermal Healing." Vitam Horm. 2016. PMID: 27450738
- Goldstein AL, Hannappel E, Kleinman HK. "Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues." Trends Mol Med. 2005. PMID: 15967726
- Chang CH, et al. "BPC 157 accelerates healing of collagenase-induced injury in rabbit Achilles tendon." J Orthop Res. 2011. PMID: 21337399
- Sikiric P, et al. "Acetylcholinesterase inhibition by BPC 157: new mechanism." CNS Neurosci Ther. 2026. PMID: 39935793
For research purposes only. Not for human or veterinary therapeutic use. Not a drug, biologic, or dietary supplement. Not evaluated by any regulatory authority for safety, efficacy, or purity in humans or animals outside controlled laboratory settings.
Products listed are intended for research purposes only.
| Trust Grade | Action | |||
|---|---|---|---|---|
Amino Asylumwc_9610 | D | $34.99Best Price $0.22/mg | In Stock | Buy |
Step One Researchwc_6427 | X | $80.00 $40.00 $80.00/mg | In Stock | Buy |
UK SARMswc_29141 | D | $44.99 $44.99/mg | In Stock | Buy |
Platinum Lion Peptideswc_130 | X | $50.00 $44.99 $50.00/mg | In Stock | Buy |
Pepvida Labswc_123 | D | $64.00 $45.00 $12.80/mg | In Stock | Buy |
Modern Research Peptideswc_4632 | X | $47.99 $47.99/mg | In Stock | Buy |
Ion Peptidewc_2781 | D | $48.00 $48.00/mg | In Stock | Buy |
Ruo Biowc_5481 | D | $48.00 $0.10/mg | In Stock | Buy |
True Peptide Labswc_1012 | X | $50.00 $50.00/mg | In Stock | Buy |
True Peptide Labswc_1012 | X | $50.00 $50.00/mg | In Stock | Buy |
TruLab Peptideswc_2335 | X | $51.00 $51.00/mg | In Stock | Buy |
Alpha Peptideswc_2084 | X | $68.21 $51.68 $68.21/mg | In Stock | Buy |
Simple Peptidewc_50 | D | $52.00 $52.00/mg | In Stock | Buy |
Alpha Omega Peptidewc_249 | D | $52.00 $52.00/mg | In Stock | Buy |
Ameano Peptideswc_7395 | X | $53.00 $53.00/mg | In Stock | Buy |
EZ Peptideswc_29945 | X | $53.00 $53.00/mg | In Stock | Buy |
Verified Peptideswc_36446 | X | $107.00 $53.50 $107.00/mg | In Stock | Buy |
Iron Mountain Labzwc_8126 | D | $54.05 $54.05/mg | In Stock | Buy |
Penguin Peptideswc_1393 | X | $58.00 $58.00/mg | In Stock | Buy |
Iron Mountain Labzwc_36937 | D | $58.78 $58.78/mg | In Stock | Buy |
Hydro Researchwc_10047002 | D | $99.00 $59.00 $99.00/mg | Out of Stock | Buy |
NuScience Peptideswc_1544 | D | $79.99 $59.99 $79.99/mg | In Stock | Buy |
Glacier Aminoswc_4231 | X | $59.99 $59.99/mg | Out of Stock | Buy |
Liberty Peptideswc_174 | X | $60.00 $60.00/mg | In Stock | Buy |
Sign in to view price trends and track how prices change over time.
No reviews yet - be the first to review this product!
Research-backed stack combining BPC-157, TB-500, and PEG-MGF for injury recovery. Explores mechanism synergy, phase-based protocols, and cost analysis.
Read articleA researcher's guide to the leading peptides investigated for cardiac protection, anti-fibrotic effects, vasodilation, and heart tissue regeneration in 2026. Compare BPC-157, TB-500, Cardiogen, Apelin, and Relaxin-2 by mechanism, evidence, and research cost.
Read articleA researcher's buyer guide to the leading peptides investigated for recovery, muscle repair, injury prevention, and endurance in sports science. Compare BPC-157, TB-500, CJC-1295/Ipamorelin, IGF-1 LR3, and Follistatin-344 by mechanism, evidence, and research cost.
Read article